Aztreonam |
McCoy, 2008 [7] | AZLI, 75 mg twice daily or three times daily | 28 days with 56 days of follow-up n=211 receiving inhaled tobramycin | Reduced exacerbation rates, improvement in lung function and respiratory symptoms |
Retsch-Bogart, 2009 [8] | AZLI, 75 mg three times daily | 28 days n=164 | Improvement in lung function and quality-of-life scores, and reduced hospital days |
Oermann, 2010 [9] | AZLI, 75 mg twice daily or three times daily | 28 days on, 28 days off (up to 9 cycles) n=195 | Improvements in lung function and respiratory symptoms in patients treated three times daily |
Colistin |
Jensen, 1987 [10] | CSI, 1 million units twice daily | 3 months n=40 | Improvements in symptom scores and slower decline in lung function |
Hodson, 2002 [11] | CSI or TSI, 80 mg twice daily (CSI) or 300 mg twice daily (TSI) | 4 weeks n=115 | Improvement in lung function with TSI and not CSI. Both decreased bacterial load |
Schuster, 2013 [12] | CDP or TSI, 1.6 million units twice daily (CDP) or 300 mg twice daily (TSI) | 28 days on, 28 days off (3 cycles) n=380 | CDP was demonstrated noninferior to TSI, but primary end-point regarding lung function was not met |
Tobramycin |
MacLusky, 1989 [13] | TSI, 80 mg three times daily | 32 months n=27 | Stability in pulmonary function observed in treatment group while control group showed decline |
Smith, 1989 [14] | TSI, 600 mg three times daily | 12 weeks n=22 | Improvement in symptoms and decrease in bacterial density |
Ramsey, 1993 [15] | TSI, 600 mg three times daily | 12 weeks, 28 days on, 28 days off n=71 | Improvement in pulmonary function |
Ramsey, 1999 [16] | TSI, 300 mg twice daily | 24 weeks (on/off every 28 days) n=520 | Improvement in pulmonary function and reduced hospitalisations |
Konstan, 2011 [17] | TIP or TSI, 112 mg twice daily or 300 mg twice daily | 28 days on, 28 days off (3 cycles) n=517 | Efficacy of TIP was comparable with TSI. Greater satisfaction was observed with inhalation powder |